Vestion develops tissue regenerative therapies for a variety of disease states.  Our lead products are cell therapies designed to be delivered to the heart via a minimally invasive catheter technique.  Preclinical and clinical trial evidence indicate that this approach can improve heart muscle function even decades after damage caused by a heart attack.

Vestion will commercialize proprietary cell types and products.  The first of these is designed for the safe and highly efficient treatment of diseased heart muscle.  Both allogeneic (donor cells) and autologous (patient’s own cells) therapies are supported by Vestion’s cell processing strategies.

If you'd like to get notified of updates, let us know.